Bladder inflammatory myofibroblastic tumor
diseaseOn this page
Also known as bladder inflammatory myofibroblastic neoplasminflammatory myofibroblastic bladder tumorinflammatory myofibroblastic bladder tumourinflammatory myofibroblastic neoplasm of bladderinflammatory myofibroblastic neoplasm of the bladderinflammatory myofibroblastic neoplasm of the urinary bladderinflammatory myofibroblastic neoplasm of urinary bladderinflammatory myofibroblastic tumor of bladderinflammatory myofibroblastic tumor of the bladderinflammatory myofibroblastic tumor of the urinary bladderinflammatory myofibroblastic tumor of urinary bladderinflammatory myofibroblastic tumour of bladderinflammatory myofibroblastic tumour of the bladderinflammatory myofibroblastic tumour of the urinary bladderinflammatory myofibroblastic tumour of urinary bladderurinary bladder inflammatory myofibroblastic neoplasmurinary bladder inflammatory myofibroblastic tumorurinary bladder inflammatory myofibroblastic tumour
Summary
Bladder inflammatory myofibroblastic tumor (MONDO:0006112) is a cancer. A subtype of urinary bladder neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | bladder inflammatory myofibroblastic tumor |
| Mondo ID | MONDO:0006112 |
| EFO | EFO:1000127 |
| NCIT | C6177 |
| UMLS | C1336891 |
| MedGen | 237036 |
| GARD | 0024297 |
| Anatomy (UBERON) | UBERON:0001255 |
| Is cancer (heuristic) | yes |
Also known as: bladder inflammatory myofibroblastic neoplasm · bladder inflammatory myofibroblastic tumor · inflammatory myofibroblastic bladder tumor · inflammatory myofibroblastic bladder tumour · inflammatory myofibroblastic neoplasm of bladder · inflammatory myofibroblastic neoplasm of the bladder · inflammatory myofibroblastic neoplasm of the urinary bladder · inflammatory myofibroblastic neoplasm of urinary bladder · inflammatory myofibroblastic tumor of bladder · inflammatory myofibroblastic tumor of the bladder · inflammatory myofibroblastic tumor of the urinary bladder · inflammatory myofibroblastic tumor of urinary bladder · inflammatory myofibroblastic tumour of bladder · inflammatory myofibroblastic tumour of the bladder · inflammatory myofibroblastic tumour of the urinary bladder · inflammatory myofibroblastic tumour of urinary bladder · urinary bladder inflammatory myofibroblastic neoplasm · urinary bladder inflammatory myofibroblastic tumor · urinary bladder inflammatory myofibroblastic tumour
Disease family
This is a subtype of urinary bladder neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › urinary system disorder › urinary bladder disorder › urinary bladder neoplasm › bladder inflammatory myofibroblastic tumor
Related subtypes (5): bladder benign neoplasm, urinary bladder cancer, urinary bladder villous adenoma, bladder papillary urothelial neoplasm, bladder flat intraepithelial lesion
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.